Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
eqs_en 
0 07.01.22
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
eqs_en 
0 07.01.22
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
eqs_en 
0 07.01.22
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
eqs_de 
0 07.01.22
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
eqs_de 
0 07.01.22
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

BusinessWire_EN 
0 06.01.22
Acadia Healthcare to Present at the 40th Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Present at the 40th Annual J.P. Morgan Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference, which takes place January 10 – January

BusinessWire_EN 
0 06.01.22
ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 40th Annual

BusinessWire_EN 
0 05.01.22
Premier, Inc. Announces Participation in J.P. Morgan Healthcare Conference and Date and Time for Fiscal 2022 Second-Quarter Earnings Release and Conference Call: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Announces Participation in J.P. Morgan Healthcare Conference and Date and Time for Fiscal 2022 Second-Quarter Earnings Release and Conference Call


Premier, Inc. (NASDAQ: PINC) today announced that members of its management team will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. The conference is a

BusinessWire_EN 
0 05.01.22
Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference


Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022. William Doyle, Novocure’s Executive

BusinessWire_EN 
0 04.01.22
Acadia Healthcare Announces Acquisition of CenterPointe Behavioral Health System: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Acquisition of CenterPointe Behavioral Health System


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the Company has completed the acquisition of CenterPointe Behavioral Health System, the largest dedicated behavioral healthcare

BusinessWire_EN 
0 03.01.22
DGAP-News: Evotec erhält 7,5 Mio. € Förderung für Entwicklung eines COVID-19 Medikaments: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec erhält 7,5 Mio. € Förderung für Entwicklung eines COVID-19 Medikaments
DGAP-News: Evotec erhält 7,5 Mio. € Förderung für Entwicklung eines COVID-19 Medikaments
eqs_de 
0 03.01.22
DGAP-News: Evotec receives € 7.5 m grant for development of COVID-19 therapeutic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec receives € 7.5 m grant for development of COVID-19 therapeutic
DGAP-News: Evotec receives € 7.5 m grant for development of COVID-19 therapeutic
eqs_en 
0 03.01.22
Acadia Healthcare Expands Footprint in Illinois Through Real Estate Purchase and Establishes New Behavioral Healthcare System Named Montrose Behavioral Health Hospital: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Expands Footprint in Illinois Through Real Estate Purchase and Establishes New Behavioral Healthcare System Named Montrose Behavioral Health Hospital


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has completed the acquisition of the real estate for three currently non-operational facilities, including one adult hospital

BusinessWire_EN 
0 20.12.21
Acadia Healthcare Forms Joint Venture with Fairview Health Services: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture with Fairview Health Services


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Fairview Health Services, one of Minnesota’s leading health systems. Through this partnership

BusinessWire_EN 
0 16.12.21
Gerresheimer AG: Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases
Gerresheimer AG: Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases
eqs_en 
0 16.12.21
Gerresheimer AG: Gerresheimer schließt Vereinbarung mit bekanntem US-BioTech Unternehmen zur Entwicklung einer innovativen Pumpe ab: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer schließt Vereinbarung mit bekanntem US-BioTech Unternehmen zur Entwicklung einer innovativen Pumpe ab
Gerresheimer AG: Gerresheimer schließt Vereinbarung mit bekanntem US-BioTech Unternehmen zur Entwicklung einer innovativen Pumpe ab
eqs_de 
0 16.12.21
DGAP-News: Evotec receives US$ 18 m grant for women's health: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec receives US$ 18 m grant for women's health
DGAP-News: Evotec receives US$ 18 m grant for women's health
eqs_en 
0 16.12.21
DGAP-News: Evotec erhält 18 Mio. US$ Förderung im Bereich Frauengesundheit: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec erhält 18 Mio. US$ Förderung im Bereich Frauengesundheit
DGAP-News: Evotec erhält 18 Mio. US$ Förderung im Bereich Frauengesundheit
eqs_de 
0 16.12.21
Acadia Healthcare Forms Joint Venture With SCL Health to Build a New Behavioral Health Facility in Denver Metro Area: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture With SCL Health to Build a New Behavioral Health Facility in Denver Metro Area


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with SCL Health, one of Colorado’s premier healthcare systems. The new partnership will build a new

BusinessWire_EN 
0 14.12.21
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
eqs_en 
0 12.12.21
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
eqs_en 
0 12.12.21
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
eqs_de 
0 12.12.21
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
eqs_de 
0 12.12.21
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

BusinessWire_EN 
0 12.12.21